Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment.
Debbie S DebenBjorn WinkensSofia A W van MoorselBrigit P C van OijenPaul BusMarieke J PierikMelek SimsekNanne K H de BoerMathie P G LeersDennis R WongAdriaan A van BodegravenPublished in: British journal of clinical pharmacology (2024)
Thiopurine metabolite concentrations at T1 were related to early treatment discontinuation and skewed metabolism at steady state, but not to effectiveness, helping to identify patients with a high risk of thiopurine treatment failure.